UPMC’s acquisition of Susquehanna Health comes with $500 million in improvements

The four-hospital Susquehanna Health system is officially a part of the University of Pittsburgh Medical Center (UPMC), with the deal including $500 million in renovations and upgrades at the newly acquired facilities.

The acquisition became official Oct. 18 after first being announced in May. The president of the rechristened UPMC Susquehanna, Steven Johnson, said the affiliation will “bring a new level of innovation and advanced care” to central Pennsylvania.

“Today marks a new era of healthcare for our region,” Johnson said. "Building on our strong clinical quality and patient safety track record, emphasis on caring for patients and expertise in delivering care to all of the communities we serve, including rural communities, Susquehanna Health is even stronger with UPMC."

To show “its commitment” to the region, UPMC said it will invest $500 million in the system. Among the planned improvements are expanding emergency, vascular and cancer services, creating an urgent care network and neurosciences center, and building a new inpatient rehabilitation facility, replacing one built in the 1960s.

Services offered at the Susquehanna Health hospitals won’t be outsourced, Johnson said, and UPMC emphasized the local governance of the facilities will be maintained.

“With UPMC’s leading integrated health care delivery and insurance model, we also share with Susquehanna the same firm commitment UPMC has proven in other communities, and that is to keep high-quality, affordable care locally accessible and close to home for our patients,” said UPMC executive vice president and CMO Steven Shapiro, MD. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.